Related Experiment Video
Updated: May 22, 2026
11:02
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Perspectives for metabolomics in testosterone replacement therapy.
1Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Strasse, D-17475 Greifswald, Germany. robin.haring@uni-greifswald.de
The Journal of Endocrinology
|May 2, 2012
Summary
This review addresses uncertainties in diagnosing and treating androgen deficiency syndrome (ADS) in aging men. Metabolomics offers potential for improved diagnosis, personalized treatment, and monitoring of testosterone replacement therapy.
Area of Science:
- Endocrinology
- Metabolomics
- Men's Health
Background:
- Testosterone levels decline with age in men.
- Late-onset hypogonadism, or androgen deficiency syndrome (ADS), is characterized by low testosterone and various clinical symptoms.
- Uncertainties exist regarding ADS diagnosis, treatment goals, and monitoring parameters due to unspecific symptoms.
Purpose of the Study:
- To review current uncertainties in the diagnosis, therapy, and monitoring of androgen deficiency syndrome (ADS).
- To explore the emerging role of metabolomics in managing ADS.
- To discuss the potential of metabolomics and other 'omics' for biomarker discovery and personalized testosterone replacement therapy.
Main Methods:
- Literature search of the PubMed database.
- Review of current research on metabolomics and its application in disease diagnosis, prognosis, and treatment monitoring.
- Exploration of 'omics' technologies for biomarker discovery.
Main Results:
- Metabolomics is increasingly impacting disease diagnosis, prognosis, and monitoring of drug efficacy and safety.
- The application of metabolomics in clinical management of ADS is discussed.
- Opportunities for personalized testosterone replacement therapy using 'omics' are highlighted.
Conclusions:
- Significant uncertainties remain in the clinical management of androgen deficiency syndrome (ADS).
- Metabolomics presents a promising avenue for improving diagnostic accuracy, treatment efficacy, and safety monitoring in ADS.
- Future research leveraging 'omics' technologies can lead to individualized testosterone replacement strategies for men.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Testosterone: Functions and Regulation
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...